Cambridge Healthtech Institute’s Eleventh Annual 

Translational to Clinical R&D

Strategies and Technologies to Reduce Attrition and Improve Clinical Outcomes

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

Despite the many breakthroughs in high-throughput omics, a deeper understanding of disease biology, and increased investments in R&D, the delivery of innovative therapies to patients in need has rapidly declined—with significant clinical hurdles during transition from phase II to III. Effectively and efficiently translating novel science into clinical settings has the potential to accelerate the development of new medicines, while increasing the odds of success throughout clinical research. Yet, how do developers find practical ways to overcome the translational challenges resulting in high rates of attrition? What are emerging modalities poised to deliver highly efficacious and safer therapies? What strategies derived from novel science and technologies are improving the translation from benchtop to bedside?

Cambridge Healthtech Institute’s Translational to Clinical R&D is designed to convene thought leaders working in early discovery and development to bring forth emerging strategies for improving therapeutic intervention, increasing R&D efficiency using novel science and technologies, and ultimately ensuring the right therapy is developed for the right target and reaches the right patients in need.


IMPROVING TRANSLATION & SUCCESS OF ADCS IN THE CLINICAL

Featured Presentation: Talk Title to be Announced

Jonathan Drachman, M.D., CMO & Executive Vice President, Research and Development, Seattle Genetics

Emerging Strategies to Improve Success with ADCs in Oncology

Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen

Target, Drug and Linker Selection Strategies for Antibody-Drug Conjugates

Hans-Peter Gerber, Ph.D., Vice President, BioConjugates Discovery & Development, Oncology Research Unit East, Pfizer Worldwide Research and Development

Improving Efficacy of Antibody Drug Conjugates

Alan Wahl, Ph.D., Vice President, Research and Discovery, Ambrx, Inc.

Translational Safety of Immunostimulatory and ADC Cancer Biologics

Rakesh Dixit, Ph.D., DABT, Vice President, R&D; Global Head Biologics Safety Assessment, Pathology and LAR, MedImmune (AstraZeneca Biologics)


considerations for development of Immunotherapies and combinations

Biomarkers in Cancer Immunotherapy

Ira Mellman, M.D., Vice President, Cancer Immunology, Genentech

Strategies for Clinical Development of Cancer Immunotherapy

Roy Baynes, M.D., Senior Vice President, Global Clinical Development, Merck

Translational Strategies for the Clinical Development of Immunomodulatory Antibodies

Robert Pierce, M.D., CMO, OncoSec Medical, Inc.

Preclinical Validation of Immunotherapies and Combination Strategies for Cancer

James Smothers, Ph.D., Senior Director; Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline


Adoptive t-Cell THERAPy SPOTLIGHT: Chimeric Antigen receptors (CARs)

CAR T Cell Therapy: Target Antigen Discovery and Clinical Translation

Richard Morgan, Ph.D., Vice President, Immunotherapy, Bluebird Bio

Predictive Biomarkers in Adoptive T Cell Therapy

Laszlo Radvanyi, Ph.D., CSO, Lion Biotechnologies

Talk Title to be Announced

Jennifer Brogdon, Ph.D., Senior Investigator, Oncology Cell Therapies, Novartis Institutes for BioMedical Research, Inc.


Predictive Pre-Clinical Models

Overcoming ADC Resistance in Pre-Clinical Models

Frank Loganzo, Ph.D., Director, Oncology, Pfizer

T Cell Biology in a 3D Cell Culture System

David Colter, Ph.D., Principal Scientist, Biologics Research, Janssen


ADVANCES IN IMAGING FOR TRANSLATABLE BIOMARKERS

Impact and Translational Opportunities of Preclinical Imaging in Biomarker Discovery and Drug Development: Case Study in ADCs

Paul J. McCracken, Ph.D., Director, Imaging Biomarkers and Personalized Medicine, Eisai

Utilizing Imaging to Guide Development of ADCs

Simon Williams, Ph.D., Principal Scientist, Biomedical Imaging, Genentech


BIOMARKER DEVELOPMENT AND DISEASE MODELING

The Impact of Tumor Heterogeneity on Clinical Biomarker Development Using PPFE Tissue

Ken Chang, Ph.D., Senior Principal Scientist, Molecular Biomarkers and Diagnostics, Merck Clinical Labs

Orion Bionetworks, a Novel Cooperative Partnership for Systems Modeling and Biomarker Discovery for Brain Diseases

Magali Haas, M.D., Ph.D., Founder and CEO, Orion Bionetworks

Identifying and Overcoming Markers of Chemoresistance

Jason Baum, Ph.D., Associate Director, Companion Diagnostics, Research, Merrimack Pharmaceuticals


Additional Presentation Sponsored by

 


 For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

 

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 


Local Partners:

BayBio 


biocube 


Cabs 

City of SSF